Cardiovascular outcomes in type 2 diabetes: A double-blind placebo- controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park diabetes cardiovascular disease prevention (SENDCAP) study

Diabetes Care

Volumn 21, Issue 4, 1998, Pages 641-648

  Elkeles, Robert S ^a,e   Diamond, Judith R ^a   Poulter, Clare ^a   Dhanjil, Surinder ^a   Nicolaides, Andrew N ^a   Mahmood, Shahid ^a   Richmond, William ^a   Mather, Hugh ^b   Sharp, Patrick ^c   Feher, Michael D ^d  

^a ST MARY S HOSPITAL   (United States)

^b EALING HOSPITAL   (United Kingdom)

^c NORTHWICK PARK HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; B SCAN; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; ELECTROCARDIOGRAM; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTILIPEMIC AGENTS; BEZAFIBRATE; CAROTID ARTERIES; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; EXERCISE TEST; FEMALE; FEMORAL ARTERY; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PLACEBOS; TIME FACTORS; TRIGLYCERIDES;

EID: 0031922041     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.4.641     Document Type: Article

References (43)

1. Pyörälä K, Laakso M: Macrovascular disease in diabetes. In Diabetes in Epidemiological Perspective. Mann J, Pyörälä K, Teuscher A, Eds. London, Churchill Livingstone, 1983, p. 183-247
2. Austin M: Plasma triglyceride as a risk factor for coronary heart disease. Am J Epidem 129:249-259, 1989
3. Manninen V, Tenkanen L, Koskinen P, Huttunen J, Heinonen OP, Frick OP: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease in the Helsinki Heart Study Circulation 85:37-45, 1992
4. West KM, Ahuja MMS, Bennet PH, Czyzk A, Costa OM, Fuller J, Grab B, Garbauskas V, Jarrett J, Kosaka K, Keen H, Krolewski AS, Miki E, Schliack V, Teuscher A, Watkins PJ, Stober JA: The role of circulating glucose and triglyceride concentrations and their interactions with other risk factors as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 6:361-369, 1983
5. Laakso M, Lehto S, Penttila I, Pyörälä K: Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin dependent diabetes. Circulation 88:1421-1430, 1993
6. Seviour PW, Teal TK, Richmond W, Elkeles RS: Serum lipids, lipoproteins and macrovascular disease in non-insulin dependent diabetics: a possible new approach to treatment. Diabet Med 5:166-171, 1988
7. Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S, Miller GJ, North WRS, Stirling Y, Thompson SG: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet ii:533-537, 1986
8. Ganda OP, Arkin CF: Hyperfibrinogenemia: an important risk for vascular complications in diabetes. Diabetes Care 15:1245-1250, 1992
9. The Lipid Research Clinic Program: The Lipid Research Clinics Coronary Primary Prevention Study Trial Results II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365-374, 1984
10. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA, Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle aged men with dyslipidaemia: safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl JMed 317:1237-1245, 1987
11. Shepherd J, Cobbe S, Ford I Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 333:1301-1307, 1995
12. Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KGMM: Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 13:855-863, 1990
13. Almer L, Kjellstrom T: The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridaemia. Atherosclerosis 61:81-85, 1986
14. Grobbee DE, Bots ML: Carotid artery intima media thickness as an indicator of generalised atherosclerosis. J Int Med 236:567-573, 1994
15. Belcaro G, Nicolaides AN, Laurora G, Cesarone MR, De Sanctis MD, Incandela L, Barsotti A: Ultrasound morphology classification of arterial wall and cardiovascular events in a 6-year follow up. Arterioscler Thromb Vase Biol 16:851-856, 1996
16. Salonen R, Salonen JT: Progression of carotid atherosclerosis and its determinants: population-based ultrasonography study. Atherosclerosis 81:33-40, 1990
17. Geroulakos G, Ramaswami G, Veller MG, Fisher GM, Renton S, Nicolaides A, Waldron HA, Diamond J, Elkeles RS: Arterial wall changes in type 2 diabetic subjects. Diabet Med 11:692-695, 1994
18. Veller MG, Fisher CM, Nicolaides AN, Renton S, Geroulakos G, Stafford N, Sarker A, Szendro G, Belcaro G: Measurement of the ultrasonic intima-media thickness in normal subjects. J Vasc Surg 17:719-725, 1993
19. Rose GA, Blackburn H: Cardiovascular Survey Methods. Geneva, Switzerland, WHO Monograph Series, 1968 (mongr. no. 56)
20. Salmasi AM, Nicolaides AN, Vecht RJ, Hendry WG, Salmasi SN, Nicolaides EP, Kidner PH, Bestermann EMM: Electrocardiographic chest wall mapping in the diagnosis of coronary artery disease. Br Med J 287:9-12, 1983
21. Jarret RJ, McCartney P, Keen H: The Bedford Survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 22:79-84, 1982
22. Garg A, Grundy S: Management of dyslipidaemia in NIDDM. Diabetes Care 13:153-169, 1990
23. Jeck T, Riesen WF, Keller U: Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM. Diabet Med 14:564-570, 1997
24. Rubies-Prat J, Reverter JL, Senti M, PedroBotet J, Salinas I, Lucas A, Nogues X, Sanmarti A: Calculated low density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 16:1081-1086, 1993
25. Salonen JT, Salonen R: Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87 (Suppl. 11)11:56-65, 1993
26. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu C, Liu C, Mack WJ, Alaupovic P: Beneficial effects of Colestipolniacin therapy on the common carotid artery Circulation 88:20-28, 1993
27. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hunninghake DB, Lefcowitz DS, Probsfield J, Riley WA, Young B: Effect of lovostatin on early carotid atherosclerosis and cardiovascular events. Circulation 90:1679-1689, 1994
28. Crouse JR, Byington PR, Bond MG, Espeland A, Craven TE, Sprinkle JW, McGovern ME, Furberg CD: Pravastatin, Lipids and Atherosclerosis in the Carotid Arteries (PUC-II). Am J Cardiol 75:455-459, 1995
29. Adams MR, Nakagomi A, Keech A, Robinson J, McCredie R, Bailey B, Freedman SB, Celermajer DS: Carotid intima media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation 92:2127-2134, 1995
30. Kanters SDJ, Algra A, Banga J-D: Carotid intima-media thickness in hyperlipidemic type I and type II diabetic patients. Diabetes Care 20:276-280, 1997
31. Bonora E, Tessari R, Micciolo R, Zenere M, Targher G, Padovani R, Falezza G, Muggeo M: Intimal-medial thickness of the carotid artery in nondiabetic and NIDDM patients. Diabetes Care 20:627-631, 1997
32. Elkeles RS, Diamond JR, El-Bahgouti N, Dhanjil S, Nicolaides A, Geroulakos G, Renton S, Anyaoku V, Richmond W, Mather H, Sharp P, the SENDCAP Study Group: Relative fasting hypoinsulinaemia and ultrasonically measured early arterial disease in type 2 diabetes. Diabet Med 13:247-253, 1996
33. Ledet T, Heickendorff L, Rasmussen LM: Pathology of macrovascular disease. In Clinical Endocrinology and Metabolism: Non-Insulin Dependent Diabetes. Nattrass M, Hale PJ, Eds. London, Bailliere Tindall, 1988, p. 391-405
34. Espeland MA, Craven TE, Riley WA, Corson J, Romont AR, Furberg CD, for the Asymptomatic Carotid Artery Progression Study Research Group: Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thickness. Stroke 27:480-485, 1996
35. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, deFaire U: Angiographic assess- ment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347:849-853, 1996
36. Diabetes Drafting Group: Prevalence of small and large vessel disease in diabetic patients from 14 centres: the World Health Organization Multinational Study of Vascular Disease in Diabetics. Diabetologia 28:615-640, 1985
37. Riley CG, Oberman A, Sheffield LT: Electrocardiographic changes after glucose ingestion. Arch Int Med 130:703-707, 1972
38. Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15:820-825, 1992
39. Pyörälä K, Pedersen TR, Kjekshus J, Faegeman O, Olsson AG, Thorgeirsson G, the Scandinavian Simvastatin Survival Study (4S) Group: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
40. Burke AP, Farb AF, Malcom GT, Liang Y-H, Smialek J, Virman R: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 336:1276-1282, 1997
41. Levine GN, Keaney JF, Vita JA: Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 332:512-520, 1995
42. Goodfellow J, Ramsey MW, Luddington Jones CJH, Coates PA, Dunstan F, Lewis ML, Owens DR, Henderson AH: Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes. BMJ 312:744-745, 1996
43. Elkeles RS, Chakrabati R, Vickers M, Stirling Y, Meade TW: Effect of treatment of hyperlipidaemia on haemostatic variables. Br Med J 281:973-974, 1980